10-K: TAO Synergies Pivots to AI Crypto, Reports $10.5M Digital Asset Loss

TAO Synergies Inc. has shifted its core business from biopharmaceutical development to a cryptocurrency treasury strategy focused on Bittensor's TAO token, reporting a significant unrealized loss on digital assets for 2025.

Summary

• TAO Synergies Inc. (formerly Synaptogenix, Inc.) has undergone a significant business transformation, pivoting from biopharmaceutical development to a cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor.
• The company's strategy involves allocating between 75% and 100% of its excess cash to purchasing TAO and staking it for revenue generation and capital appreciation.
• For the year ended December 31, 2025, the company reported $299,061 in revenue from TAO staking.
• A net loss of $28,737,448 was reported for 2025, a substantial increase from $12,768,549 in 2024.
• The company incurred an unrealized loss of approximately $10.5 million on its digital asset holdings in 2025.
• Cash and cash equivalents decreased significantly from $17,656,221 in 2024 to $5,497,671 in 2025.
• Working capital increased to $23,564,919 in 2025 from $16,706,587 in 2024, driven by digital currency asset value and capital raises, offset by TAO purchases and operating expenses.
• The company terminated its agreement with the Cleveland Clinic for a Multiple Sclerosis trial in December 2024 due to slow enrollment and also terminated the Mount Sinai Agreement on February 24, 2026, further reducing its biopharmaceutical development activities.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties, ineffective period-end financial disclosure processes, and ineffective IT general computing controls.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, transformative period. While the pivot to AI crypto offers potential upside, the significant net loss, unrealized digital asset losses, and identified internal control weaknesses indicate substantial operational and financial challenges. The abandonment of biopharma programs also removes a traditional asset class, concentrating risk.

Positives

• Successfully launched a new cryptocurrency treasury strategy focused on TAO, generating $299,061 in staking revenue in 2025.
• Formed a subsidiary, TAOX Florida Inc., to facilitate expansion into the cryptocurrency treasury strategy business.
• Launched 'The TAO Daily' media platform on September 22, 2025, to highlight the Bittensor ecosystem and provide resources for TAO users and investors.
• Engaged prominent advisors James Altucher and Joseph Jacks for crypto portfolio management and strategic advice.
• Successfully raised capital through Series D and Series E Private Placements in 2025, securing approximately $14.9 million in net proceeds.
• Received approximately $10.0 million from investor warrant exercises in 2025.
• Working capital increased by $6,858,332 to $23,564,919 as of December 31, 2025.

Negatives

• Reported a substantial net loss of $28,737,448 for the year ended December 31, 2025, a 125.1% increase from $12,768,549 in 2024.
• Incurred an unrealized loss of approximately $10.5 million on digital assets in 2025.
• Cash and cash equivalents significantly decreased from $17,656,221 in 2024 to $5,497,671 in 2025.
• Research and development expenses decreased by 79.8% to $322,225 in 2025, reflecting the winding down of biopharmaceutical programs.
• General and administrative expenses increased by 73.1% to $9,023,993 in 2025, partly due to non-cash expenses from warrants issued to crypto experts and stock options compensation.
• Terminated the agreement with Cleveland Clinic for the Multiple Sclerosis Phase 1 clinical trial in December 2024 due to slow enrollment.
• Terminated the Mount Sinai License Agreement on February 24, 2026, indicating a further reduction in biopharmaceutical development.
• Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, ineffective period-end financial disclosure processes, and ineffective IT general computing controls.

Risks

• The digital asset treasury strategy centered on TAO and participation in the Bittensor network may not be successfully implemented and exposes the company to significant operational, market, cybersecurity, and regulatory risks.
• The company's TAO-focused activities depend on the design, security, and performance of the Bittensor network, a decentralized AI blockchain with a novel incentive and consensus design, which continues to evolve and may contain defects or vulnerabilities.
• Reliance on specialized infrastructure and third-party service providers (custodians and validators like BitGo and Yuma) for critical functions such as key management, staking delegation, and node uptime, carries risks of errors, malfunctions, outages, or cybersecurity incidents leading to loss or inaccessibility of TAO.
• The regulatory environment applicable to public companies pursuing cryptocurrency treasury strategies, and to crypto asset markets, staking, and decentralized AI networks, remains uncertain and continues to evolve, potentially imposing costly compliance requirements or restricting activities.
• Future classification of TAO or staking rewards as securities, commodities, or other regulated instruments could impose significant compliance obligations, increase costs, or limit the company's ability to continue current activities.
• The company's financial results are heavily dependent on TAO, significantly increasing exposure to crypto asset market volatility, valuation uncertainty, and concentrated credit risks.
• A significant percentage of TAO tokens in circulation is concentrated among a relatively small number of holders, increasing the risk of outsized influence over governance decisions and market stability.
• Accurately valuing crypto assets like TAO can be challenging, especially during periods of market stress, leading to unreliable valuations and potential unintended tax liabilities.
• The company may lack effective tools to hedge against TAO's price volatility, as no established derivatives market exists for TAO, leaving it exposed to adverse market swings.
• TAO holdings are illiquid and may be difficult to sell or use as collateral, potentially impairing the ability to meet financial obligations during market instability.
• Managing crypto assets introduces operational complexities and control risks distinct from traditional treasury functions, with failures in private key security, wallet controls, or transaction protocols potentially resulting in irreversible losses.
• The open-source and decentralized design of crypto asset networks, including Bittensor, exposes the company to risks related to forks, airdrops, incidental rights, and related technological and operational disruptions.
• The irreversibility of crypto asset transactions exposes the company to risks of theft, loss, and human error, as incorrect transfers or thefts are generally not recoverable.
• Decentralized AI networks, such as Bittensor, involve special risks related to unclear regulatory requirements, technical difficulties (e.g., model inaccuracies, embedded biases), limited transparency, intense competition, and complex intellectual property considerations.
• Subtensor's current use of a proof-of-authority model for transaction ordering and finality centralizes control, increasing the risk of network halts, delayed processing, or selective censorship.
• The company is not subject to legal and regulatory obligations that apply to investment companies or investment advisers, meaning investors do not benefit from heightened protections under those acts.
• The company's ownership and operation of 'The TAO Daily' media platform presents risks from perceived or actual conflicts of interest, potentially influencing TAO trading prices or damaging reputation.
• The company's ongoing viability partially depends on its ability to successfully develop and commercialize its licensed biopharmaceutical technology, which has faced setbacks (Bryostatin-1 Phase 2 failures, MS trial termination).
• The company relies on independent third-party contract research organizations (CROs) for clinical and non-clinical studies, leading to potential issues with control, compliance, or disputes.
• The company is partly dependent upon the NCI to supply bryostatin for its clinical trials, with no assurance of future supply on commercially reasonable terms.
• Failure to maintain effective internal control over financial reporting, as evidenced by identified material weaknesses, could materially and adversely affect the company's ability to report financial information timely and accurately.

Future Outlook

The company expects to continue accumulating TAO tokens over time, viewing its holdings as long-term investments. It is exploring the potential implementation of hedging strategies to manage digital asset price volatility, though none have been implemented to date. The company may also explore additional yield-enhancement strategies, including participation in Bittensor subnets, likely with a third-party partner. Current cash, cash equivalents, and digital assets, totaling approximately $27 million, are expected to support projected operating requirements for at least the next 12 months. However, additional capital will be required to continue pursuing the TAO treasury strategy and to advance any remaining biopharmaceutical development, with continued losses and negative cash flows from operations anticipated for at least the next several years.

Management Comments

• Our differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI, underscores our mission to create significant value for shareholders.
• We view our TAO holdings as long-term holdings and expect to continue accumulating TAO over time.
• We are exploring the potential implementation of hedging strategies to manage risks associated with digital asset price volatility; we have not implemented any hedging strategies to date, and there can be no assurance that any such strategies will be implemented or, if implemented, effective.
• We expect that our current cash and cash equivalents and digital assets of approximately $27 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Annual Report on Form 10-K.
• We expect to require additional capital in order to initiate, pursue and complete all potential AD clinical trials and obtain regulatory approval of one or more therapeutic candidates.

Industry Context

StockSavvy.ai notes that TAO Synergies' pivot from biopharmaceutical R&D to an AI crypto treasury strategy is a bold move, aligning with the growing interest in decentralized AI and blockchain technologies. This positions the company to potentially capitalize on the convergence of AI and crypto, a sector attracting significant investment and innovation. However, it also exposes them to the inherent volatility and regulatory uncertainties of the nascent crypto market, a stark contrast to the more traditional, albeit challenging, biopharmaceutical sector. The launch of 'The TAO Daily' indicates an attempt to become a thought leader and information hub within the Bittensor ecosystem, potentially enhancing their influence and investment thesis in this niche. This strategic shift is a significant departure from the typical operations of a publicly traded company, highlighting a willingness to embrace high-risk, high-reward opportunities in emerging tech sectors.

Comparison to Industry Standards

• The company's shift from biopharmaceutical development, particularly in Alzheimer's disease, follows a pattern seen in the industry where drug candidates often fail to meet statistical significance in later-stage clinical trials. Many large pharmaceutical companies, such as Pfizer and Eli Lilly, have faced similar setbacks in AD research, leading to high R&D costs and limited successful product introductions in the last 20 years.
• The adoption of a cryptocurrency treasury strategy, specifically focusing on a single 'pure play AI crypto coin' like TAO, is a highly unconventional move for a publicly traded company, especially one previously in biopharma. This contrasts sharply with traditional corporate treasury management, which typically prioritizes stability and liquidity through low-risk assets like government bonds or FDIC-insured accounts.
• While some companies like MicroStrategy have adopted Bitcoin as a primary treasury asset, TAO Synergies' focus on TAO, a smaller market cap, AI-specific token, represents a significantly higher risk and concentration compared to broader crypto market exposure or traditional asset management.
• The reported unrealized loss of $10.5 million on digital assets in 2025 highlights the extreme volatility inherent in this strategy, which is not comparable to the stable returns expected from traditional treasury assets.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings against the company, and the company is unaware of any such proceedings contemplated against it.

Related Party Transactions

• Consulting Agreement with SM Capital Management, LLC (owned by Executive Chairman Joshua N. Silverman) for $120,000 annually, superseded by the Silverman Compensation Agreement effective July 1, 2025.
• Joshua N. Silverman's Executive Compensation Agreement (effective July 1, 2025) includes an annual base salary of $360,000, eligibility for performance-based bonuses, and annual long-term incentive awards.
• Dr. Daniel L. Alkon's consulting agreement (Alkon Consulting Agreement) with reduced monthly salary ($12,500, then $1,500) and incentive fees for Bryostatin asset transactions, which was terminated effective October 10, 2025.
• Robert Weinstein's employment agreement (assumed from Neurotrope) includes an annual base salary and eligibility for discretionary annual bonuses.
• The CRE License Agreement with Cognitive Research Enterprises, Inc. (CRE), a related party, for intellectual property and research services, requires the company to reimburse CRE for patent prosecution and maintenance costs.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity/debt financings. High volatility and potential for substantial losses due to concentrated TAO holdings. Uncertainty regarding the success of the new crypto strategy and the future of biopharma assets. Potential for delisting from Nasdaq due to market price fluctuations.
• **Employees**: The shift in business strategy may impact roles and required skill sets, particularly with the winding down of biopharma R&D. The company's success is highly dependent on key personnel like James Altucher in the new crypto venture.
• **Customers (Biopharma)**: The discontinuation of the MS trial and termination of the Mount Sinai agreement reduces potential future treatments for neurodegenerative diseases. Uncertainty surrounds the continued development of Bryostatin-1 for Alzheimer's disease.
• **Customers (TAO Daily)**: The media platform aims to provide news and insights, potentially benefiting TAO users and investors, but perceived conflicts of interest due to company ownership could affect trust and credibility.
• **Suppliers/Creditors**: The company's financial condition, marked by net losses and digital asset volatility, impacts its ability to meet obligations. Capital raises provide liquidity but also introduce new debt/equity obligations and associated covenants.

Next Steps

• Continue accumulating TAO tokens as part of the long-only treasury strategy.
• Explore potential implementation of hedging strategies for digital asset price volatility.
• Evaluate additional yield-enhancement strategies, including participation in Bittensor subnets, potentially with a third-party partner.
• Determine next steps for the development of Bryostatin-1 for Alzheimer's disease and other potential indications.
• Evaluate plans to advance Fragile X development, addressing the FDA's clinical hold.
• Seek stockholder approval for matters related to the Series E Preferred Stock issuance (more than 19.99% of outstanding common stock).
• Remediate identified material weaknesses in internal control over financial reporting, including improving segregation of duties, financial disclosure processes, and IT general computing controls.
• Monitor market conditions, liquidity needs, and financing opportunities for future TAO purchases.

Key Dates

Recommendation

The company's abrupt pivot from biopharmaceutical R&D to a highly speculative AI crypto treasury strategy, coupled with substantial unrealized losses on digital assets ($10.5 million) and a significantly increased net loss ($28.7 million) in 2025, presents extreme risk. While the new strategy aims for capital appreciation and yield, it introduces immense volatility, regulatory uncertainty, and concentration risk in a single, relatively illiquid crypto asset (TAO). The identified material weaknesses in internal controls further compound operational risks. The abandonment of clinical trials for Bryostatin-1 removes any near-term traditional value drivers. For a seasoned investor, the current risk-reward profile is unfavorable, warranting a 'sell' recommendation due to the highly speculative nature, significant financial losses, and operational uncertainties.

Keywords

TAO, Bittensor, Cryptocurrency, AI, Staking, Digital Assets, Treasury Strategy, Blockchain, Biopharmaceutical, Alzheimer's Disease, Fragile X Syndrome, Multiple Sclerosis, SEC Filing, 10-K, Financial Report, Corporate Governance, Risk Management, BitGo, Yuma Validator, Market Volatility, Regulatory Uncertainty, Internal Controls